certepetide
Peptide
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
Company guidance: data expected in 2026 (NCT05042128; Lisata Therapeutics, 13 Nov 2026). “Additional data from Cohorts A and B was presented at the ESMO annual meeting in October 2025 with a final study report of the ASCEND study anticipated to be made available in 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03517176 NCT03517176 · Pancreatic Cancer Registry: NCT03517176 | 1 | Safe doses of CEND-1 when given alone or in combination with nabpaclitaxel and gemcitabine (Escalation Phase: From Day 1 of the run-in until Day 28 of Cycle 1 (cycle length=28 days)); Optimal Biological Dose (OBD) of CEND-1 when given in combination (Expansion Phase: from baseline until treatment discontinuation and approximately 30 days after last dose (cycle length=28 days)) 2020-06-19 | Phase 1 of CEND-1 (certepetide) plus nab-paclitaxel and gemcitabine: no dose-limiting toxicities in 31 patients. | not yet graded | link ↗ |
View 2 more trials
NCT06261359 NCT06261359 · Pancreatic Cancer Registry: NCT06261359 | 2 | Objective response rate (ORR) (Approximately 36 months) 2025-04 | In progress: primary completion was expected 1 Apr 2025; results not posted | not yet graded | link ↗ |
ASCEND NCT05042128 · Pancreatic Cancer Registry: NCT05042128 | 2 | Progression Free Survival (From date of randomization to 18 months later, or death) 2025-06-01 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Pancreatic Cancer: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Certepetide: this drug | Phase 2 | Peptide | Alpha-v integrins and neuropilin-1 (CendR tumour-penetration pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Erlotinib | Approved | Small molecule | EGFR | Partial signal | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Atebimetinib | Phase 3 | Small molecule | MEK (MAP2K1/2) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4642 | Phase 3 | Undisclosed | KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Tertomotide | Phase 3 | Peptide | Telomerase (hTERT) | not yet graded | No reviewed efficacy summary in this indication | |
| Zoldonrasib | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Motixafortide | Phase 2 | Peptide | CXCR4 | not yet graded | No reviewed efficacy summary in this indication | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Phase 2 | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| A2B530 | Phase 1/2 | Cell therapy | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker) | not yet graded | No reviewed efficacy summary in this indication | |
| KRAS-Specific Autologous TCR-T Cell | Phase 1(overall) | Cell therapy | KRAS G12V presented on HLA-A*11:01 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent